ReviewFrontiers in cardiovascular medicine2025
Role of circadian transcription factor REV-ERB in cardiovascular diseases: a review.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Dihydroergotamine alleviates circadian rhythm disorders through predicted interaction with to CRY1.Molecular diversity · 2026Article
- D-Box Binding Protein (DBP) as a Circadian Output Regulator: Molecular Mechanisms, Tissue-Specific Functions, and Disease Relevance.International journal of molecular sciences · 2026Review
- Integrative Machine-Learning Molecular Subtyping and Risk Scores of Circadian Rhythm-Related Prognostic Signatures in Colorectal Cancer.Journal of gastrointestinal cancer · 2026Article
- Gut microbiota-derived lactate is associated with disrupted cardiac circadian rhythms in alcoholic heart disease.NPJ biofilms and microbiomes · 2026Article
- RORγtScience immunology · 2026Article
- Chronopharmacology-Driven Precision Therapies for Time-Optimized Cardiometabolic Disease Management.Biology · 2026Review
- The Circadian Rhythm of Asthma Immune Metabolism.Journal of immunology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circadian rhythm, or the biological clock, is an intrinsic timing system present in organisms that operates on a cycle of approximately 24 h. Nearly every cell in the human body adheres to a specific circadian rhythm, governing various biological processes essential for overall health. REV-ERB, a key circadian clock-regulating gene, plays a crucial role in maintaining the precision of these rhythms. This gene influences many downstream targets associated with diverse pathophysiological processes, including metabolism, autophagy, immunity, inflammation, and aging across multiple organs. REV-ERB specifically impacts cardiac systolic function by regulating myocardial energy metabolism. In contemporary society, health and well-being are increasingly challenged by disruptions to the biological clock, such as night shifts, late-night activities, and jet lag. These disruptions often lead to circadian rhythm disorders, which are now being increasingly linked to heart diseases. This review explored the potential role of REV-ERB in the cardiovascular system. Beyond its role in circadian rhythm regulation, REV-ERB could significantly influence physiological and pathological processes related to cardiovascular health, including atherosclerosis, myocardial ischemia/reperfusion injury, and heart failure. Mechanistically, REV-ERB could regulate glucose and lipid metabolism, inflammation, autophagy, ferroptosis, and mitochondrial function. The review highlighted the protective roles and underlying mechanisms of REV-ERB in cardiovascular diseases, suggesting that multidisciplinary research may provide a basis for breakthroughs in REV-ERB-targeted therapies for cardiovascular disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.